Celaid Therapeutics Raises $3.08Mn in Series B to Advance Pediatric HSC Therapy

The company creates stem cell treatments for children who have serious non-cancer diseases. The recent money will help in developing its main treatment called CLD-001 and will help push forward its HSC-based treatment programs.

The latest Series B part brings the money raised by Celaid Therapeutics to about twenty-six million three hundred thousand dollars, including grants.

How will Celaid Therapeutics use the money?

Celaid Therapeutics wants to use the money to move forward with CLD-001, its main HSC therapy treatment.

The company is working on creating treatments for pediatric non-cancer diseases. In these cases better stem cell treatments could help with needs that are not being met.

What is Celaid Therapeutics?

Celaid Therapeutics is a biotechnology company that started from the University of Tokyo and the University of Tsukuba.

The company has made technology for the selective growth of hematopoietic stem cells outside the body. HSCs are the cells that create all the blood cells in the human body.

Celaids technology is meant to help grow HSCs safely and effectively outside the body. The company is using this technology in areas such as HSC-based treatments for blood and diseases HSC gene treatments outside the body and regenerative medicine for diseases where blood flow is limited.

About Celaid Therapeutics

Founded based on research from the University of Tokyo and the University of Tsukuba Celaid Therapeutics is working on cell and gene treatments by using its HSC growth technology. Its current work includes treatments, for pediatric non-cancer diseases and other illnesses that could benefit from HSC-based treatments.

Read Also - Singapore’s OneByZero Secures $20 Mn Series A to Expand Enterprise AI Operations